Prestige Consumer Healthcare (NYSE:PBH) Downgraded by Zacks Research to “Strong Sell”

Zacks Research downgraded shares of Prestige Consumer Healthcare (NYSE:PBH) from a hold rating to a strong sell rating in a research report released on Monday,Zacks.com reports.

A number of other brokerages have also commented on PBH. Canaccord Genuity Group cut their price target on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating on the stock in a report on Friday, May 15th. Jefferies Financial Group cut their price target on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating on the stock in a report on Friday, January 30th. Weiss Ratings lowered shares of Prestige Consumer Healthcare from a “hold (c)” rating to a “hold (c-)” rating in a report on Thursday, May 14th. Finally, Oppenheimer lowered shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a report on Thursday, May 14th. Two research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Prestige Consumer Healthcare presently has a consensus rating of “Hold” and an average target price of $70.75.

Prestige Consumer Healthcare Price Performance

Shares of NYSE:PBH opened at $46.49 on Monday. The company has a market cap of $2.20 billion, a price-to-earnings ratio of 11.89, a PEG ratio of 1.50 and a beta of 0.40. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.57 and a quick ratio of 2.25. The firm has a 50 day simple moving average of $57.03 and a 200 day simple moving average of $61.17. Prestige Consumer Healthcare has a one year low of $42.62 and a one year high of $89.24.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings data on Wednesday, May 13th. The company reported $1.23 EPS for the quarter, missing the consensus estimate of $1.39 by ($0.16). The company had revenue of $281.62 million during the quarter, compared to the consensus estimate of $293.64 million. Prestige Consumer Healthcare had a net margin of 17.48% and a return on equity of 11.54%. Prestige Consumer Healthcare’s revenue for the quarter was down 5.0% on a year-over-year basis. During the same period in the previous year, the company earned $1.32 EPS. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. Research analysts predict that Prestige Consumer Healthcare will post 4.43 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, VP Jeffrey Zerillo sold 1,207 shares of Prestige Consumer Healthcare stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $54.99, for a total transaction of $66,372.93. Following the completion of the transaction, the vice president owned 42,820 shares of the company’s stock, valued at $2,354,671.80. This trade represents a 2.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 1.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Hedge funds have recently bought and sold shares of the company. AQR Capital Management LLC increased its stake in Prestige Consumer Healthcare by 11.9% in the first quarter. AQR Capital Management LLC now owns 30,056 shares of the company’s stock valued at $2,558,000 after purchasing an additional 3,200 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Prestige Consumer Healthcare by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,490 shares of the company’s stock valued at $2,535,000 after purchasing an additional 1,289 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in Prestige Consumer Healthcare by 28.4% in the first quarter. Goldman Sachs Group Inc. now owns 546,672 shares of the company’s stock valued at $46,997,000 after purchasing an additional 120,965 shares in the last quarter. Jane Street Group LLC increased its stake in Prestige Consumer Healthcare by 204.0% in the first quarter. Jane Street Group LLC now owns 104,802 shares of the company’s stock valued at $9,010,000 after purchasing an additional 70,330 shares in the last quarter. Finally, Geneos Wealth Management Inc. increased its stake in Prestige Consumer Healthcare by 92.8% in the first quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock valued at $48,000 after purchasing an additional 269 shares in the last quarter. Institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).